mRNA疫苗构建及其规模化生产的概述  

The review of construction and manufacture of mRNA vaccines

作　　者：刘鸿斌 杨俊杰 LIU Hong-bin;YANG Jun-jie(The Four Research Department,Lanzhou Institute of Biological Products Co.,Ltd.,Center for Gansu Provincial Vaccine Engineering Research,Lanzhou 730046,Gansu Province,China)

机构地区：[1]兰州生物制品研究所有限责任公司第四研究室、甘肃省疫苗工程技术研究中心,甘肃兰州730046

出　　处：《微生物学免疫学进展》2023年第1期49-55,共7页Progress In Microbiology and Immunology

摘　　要：疫苗(vaccine)是一种在公共健康领域内预防传染性疾病暴发及流行最经济有效的产品。信使核糖核酸(messenger RNA, mRNA)技术的不断发展,为mRNA疫苗这一新型疫苗在新型冠状病毒感染(corona virus disease 2019, COVID-19)大流行期间的快速研发、生产和应用奠定了基础。COVID-19在全球暴发不到一年的时间内,BNT162b2与mRNA-1273疫苗相继获批上市,从临床试验和大规模接种后的数据统计分析来看,2款疫苗均显示出了良好的安全性和保护效率。mRNA疫苗因其生产快捷的特点使其在应对突发性传染病方面拥有巨大的优势,现就mRNA疫苗的制备及现阶段在规模化生产过程中的工艺选择作一概述。Vaccine is one of the most economical and effective tools for the prevention of infectious diseases in the field of public health. The continuous development of messenger RNA(mRNA) technologies has laid foundations for the rapid research, manufacturing and application of mRNA vaccines during 2019 coronavirus(COVID-19) pandemic. Within less than one year since the outbreak of the COVID-19, two mRNA-based vaccines(BNT162b2, mRNA-1273) were approved, both of them showed a favorable safety and protection efficiency profile according to the data of clinical trials and massive vaccination. mRNA vaccine has great advantages in facing outbreak of new infectious diseases due to a rapid and flexible manufacturing process. This article mainly summarizes the preparation of mRNA vaccines, as well the selection of production process during large-scale manufacturing.

关 键 词：mRNA疫苗 传染病 规模化生产 疫苗制备 

分 类 号：R392[医药卫生—免疫学]